1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Adenovirus Infections - Pipeline Review, H1 2014

Adenovirus Infections - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 64 pages

Adenovirus Infections - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Adenovirus Infections - Pipeline Review, H1 2014’, provides an overview of the Adenovirus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenovirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenovirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adenovirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Adenovirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Adenovirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Adenovirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Adenovirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Adenovirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Adenovirus Infections - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Adenovirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Adenovirus Infections - Overview 8
Pipeline Products for Adenovirus Infections - Comparative Analysis 9
Adenovirus Infections - Therapeutics under Development by Companies 10
Adenovirus Infections - Therapeutics under Investigation by Universities/Institutes 11
Adenovirus Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Adenovirus Infections - Products under Development by Companies 15
Adenovirus Infections - Products under Investigation by Universities/Institutes 16
Adenovirus Infections - Companies Involved in Therapeutics Development 17
NovaBay Pharmaceuticals, Inc. 17
Cell Medica Limited 18
Chimerix, Inc. 19
Foresight Biotherapeutics, Inc. 20
BioApex, s.r.o. 21
Adenovirus Infections - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
brincidofovir - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
FST-100 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Cell Therapy for Infectious Diseases - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Cytovir ADV - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Multi-Virus Cytotoxic T Lymphocytes - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
NVC-727 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
BA-368 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
RKP-00156 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
hCAP-18/LL-37 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Adenovirus Infections - Recent Pipeline Updates 42
Adenovirus Infections - Dormant Projects 51
Adenovirus Infections - Product Development Milestones 52
Featured News and Press Releases 52
Mar 14, 2014: Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection 52
Mar 11, 2014: Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections 53
Sep 11, 2013: Chimerix Presents Brincidofovir Adenovirus Phase 2 Results 53
Aug 14, 2013: Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC 56
May 16, 2013: Chimerix Presents Data On CMX001 At 26th International Conference On Antiviral Research 57
Apr 29, 2013: Chimerix Presents Data On Antiviral Drug Candidate CMX001 At EBMT Annual Meeting 58
Apr 08, 2013: NovaBay Pharma Enrolls First Patients In Brazil In BAYnovation Phase IIb Study For Adenoviral Conjunctivitis 60
Mar 28, 2013: Chimerix Announces Presentation Of Data On Antiviral Compound CMX001 At EBMT Annual Meeting 61
Apr 03, 2012: Chimerix To Present Data On CMX001 At Needham And Future Leaders Conferences 61
Jan 23, 2012: NovaBay Prepares To Launch Global Phase IIb Ophthalmic Study Of NVC-422 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables

Number of Products under Development for Adenovirus Infections, H1 2014 8
Number of Products under Development for Adenovirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Adenovirus Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2014 17
Adenovirus Infections - Pipeline by Cell Medica Limited., H1 2014 18
Adenovirus Infections - Pipeline by Chimerix, Inc., H1 2014 19
Adenovirus Infections - Pipeline by Foresight Biotherapeutics, Inc., H1 2014 20
Adenovirus Infections - Pipeline by BioApex, s.r.o., H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 26
Number of Products by Stage and Route of Administration, H1 2014 28
Number of Products by Stage and Molecule Type, H1 2014 30
Adenovirus Infections Therapeutics - Recent Pipeline Updates, H1 2014 42
Adenovirus Infections - Dormant Projects, H1 2014 51

List of Figures

Number of Products under Development for Adenovirus Infections, H1 2014 8
Number of Products under Development for Adenovirus Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 27
Number of Products by Stage and Top 10 Route of Administration, H1 2014 28
Number of Products by Top 10 Molecule Type, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.